Skip to main content

Table 5 Serum tumor marker levels of patients with different subtypes of lung cancer in the test group (\( \overline{\mathrm{X}} \) ±s)

From: Clinical study of systemic chemotherapy combined with bronchoscopic interventional cryotherapy in the treatment of lung cancer

Project

SCLC

NSCLC

P Value

LADC

LSCC

P Value

Before treatment

CEA (ng/ml)

96.73 ± 9.11

96.01 ± 9.31

0.65

95.54 ± 9.78

95.82 ± 9.12

0.86

NSE (ng/ml)

88.71 ± 7.43

88.61 ± 7.51

0.94

88.63 ± 7.49

88.59 ± 7.49

0.97

CYFRA21-1 (ng/ml)

37.87 ± 5.87

37.84 ± 5.90

0.98

37.82 ± 5.88

37.85 ± 5.89

0.96

CA199 U/ml

51.78 ± 7.48

51.84 ± 7.52

0.96

51.82 ± 7.52

51.85 ± 7.51

0.98

After treatment

 CEA (ng/ml)

24.66 ± 1.55

20.25 ± 1.1

<  0.0001

20.27 ± 1.08

20.24 ± 1.09

0.87

 NSE (ng/ml)

28.15 ± 1.97

22.81 ± 1.75

<  0.0001

22.83 ± 1.73

22.79 ± 1.73

0.89

 CYFRA21-1 (ng/ml)

10.13 ± 0.13

9.55 ± 0.22

<  0.0001

9.54 ± 0.21

9.57 ± 0.2

0.38

 CA199 U/ml

29.22 ± 2.62

24.16 ± 1.7

<  0.0001

24.14 ± 1.72

24.17 ± 1.71

0.92